Major pharmaceutical companies can receive up to a million Individual Case Safety Reports (ICSRs) each year. Traditionally, processing this flood of information has been a manual, labor-intensive effort, consuming as much as 60% of a pharmacovigilance department's budget. The process involves transcribing data from emails, faxes, and call center notes into a safety database—a task ripe for error and a major bottleneck. The solution lies in automation.

The first wave of automation comes from Robotic Process Automation (RPA). These software 'bots' are configured to perform repetitive, rule-based tasks previously handled by humans. An RPA bot can, for instance, monitor a specific email inbox, open attachments, extract key information from a structured form, and enter that data directly into the safety database. It mimics the clicks and keystrokes of a data entry specialist but operates 24/7 without fatigue.

However, RPA works best with structured data. Many incoming reports are unstructured, arriving as scanned documents, faxes, or PDFs of literature articles. This is where Optical Character Recognition (OCR) technology becomes critical. OCR systems scan these documents, identify text, and convert it into a machine-readable format. Modern AI-powered OCR can even understand the context of a form, distinguishing a patient's date of birth from the date the report was filed, regardless of where it appears on the page.

Once the data is inside the system, the next automated step is triage. AI algorithms analyze the newly created case to make several critical assessments:

• Validity: Does the report contain the four minimum elements for a valid ICSR (an identifiable patient, a reporter, a suspect drug, and an adverse event)?
• Seriousness: Based on the described event (e.g., hospitalization, death), the system flags the case as serious or non-serious, which dictates regulatory reporting timelines.
• Duplicate Check: Is this a report the company has already received? A patient might report an event to their doctor, who then reports it to the drug company, and the patient might also call the company's hotline directly. This creates duplicates that must be identified and merged.

Specialized de-duplication algorithms are key to this process. Some systems use fuzzy logic to compare near-matches in patient initials, dates of birth, and event dates. More advanced tools, like vigiMatch developed by the Uppsala Monitoring Centre, use probabilistic record linkage. This method calculates a probability score that two records refer to the same patient and event, even with slight variations in the data. It's far more sophisticated than simply looking for exact matches.

By automating triage and de-duplication, companies can achieve straight-through processing for a significant number of cases. Simple, non-serious reports from post-marketing sources can be ingested, validated, checked for duplicates, and closed without any human intervention. This automated workflow can handle 50-60% of these straightforward cases.

This level of automation frees up highly trained pharmacovigilance staff from the repetitive work of manual data entry. Instead, they can focus their expertise on complex cases, signal detection, and risk management—the activities that truly protect patient safety.